Evidence map›Paper›PMID 30034819›Full record

ArticleEFORT open reviews2018

Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses.

Andreas F Mavrogenis, Vasilios G Igoumenou, Thekla Antoniadou, Panayiotis D Megaloikonomos, George Agrogiannis, Periklis Foukas, Sotirios G Papageorgiou

Open access · goldAbstract read
In one paragraph

Article in EFORT open reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andreas F MavrogenisFirst Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Greece.
Vasilios G IgoumenouFirst Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Greece.
Thekla AntoniadouFirst Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Greece.
Panayiotis D MegaloikonomosFirst Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Greece.
George AgrogiannisSecond Department of Pathology, National and Kapodistrian University of Athens, School of Medicine, Greece.
Periklis FoukasSecond Department of Pathology, National and Kapodistrian University of Athens, School of Medicine, Greece.
Sotirios G PapageorgiouSecond Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, School of Medicine, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-Langerhans cell histiocytosis (N-LCH) summarizes a group of rare diseases with different clinical presentations, pathogenesis and morphology. These include primary cutaneous N-LCH, cutaneous N-LCH with systemic involvement, and primary extracutaneous systemic forms with occasional cutaneous involvement.The juvenile (JXG) and non-juvenile xanthogranuloma (N-JXG) family of histiocytoses are N-LCH: the JXG family consisting of the JXG (cutaneous), xanthoma disseminatum (cutaneous and systemic) and Erdheim-Chester disease (ECD; systemic); and the N-JXG family consisting of the solitary reticulohistiocytoma (cutaneous), multicentric reticulohistiocytosis (cutaneous and systemic) and Rosai-Dorfman disease (RDD; systemic).ECD is a clonal disorder from the JXG family of N-LCH; RDD is a reactive proliferative entity from the non-juvenile xanthogranuloma family of N-LCH.ECD and RDD N-LCH are rare disorders, which are difficult to diagnose, with multi-organ involvement including bone and systemic symptoms, and which respond to therapy in an unpredictable way.The key to successful therapy is accurate identification at tissue level and appropriate staging. Patients should be observed and monitored in a long-term pattern. Prognosis depends on disease extent and the organs involved; it is generally good for RDD disease and variable for ECD. Cite this article:

Indexed as

boneErdheim-Chester diseasejuvenile xanthogranulomanon-juvenile xanthogranulomanon-Langerhans cell histiocytosisRosai-Dorfman disease

Identifiers

PMID30034819
PMCPMC6026883
OpenAlexW2808906184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.